上海医药（601607）(02607)发布公告，该公司将于2026年2月6日派发中期股息每10股1.2元。 ...

智通财经APP讯，上海医药(02607)发布公告，该公司将于2026年2月6日派发中期股息每10股1.2元。 ...

| 股東類型 | | 稅率 | 有關代預扣所得稅之更多補充 | | --- | --- | --- | --- | | | | | （如適用） | | 非居民企業 | | | | | | | | 如H股股東為境外H股非居民企業 | | （非中國內地登記地址） | | 10% | 股東（包括香港中央結算（代理 | | | | | 人）有限公司，其他企業代理人或 | | | | | 受託人，或其他組織及團體），本 | | | | | 公司將按10%的稅率代扣代繳企業 | | | | | 所得稅。 | | 非個人居民 | | | | | （非中國內地登記地址） | | 10% | 如H股個人股東為香港或澳門居民 | | | | | 以及其他與中國簽訂10%股息稅率 | | | | | 的稅收協議的國家的居民，或如H | | | | | 股個人股東為與中國簽訂低於10% | | | | | 股息稅率的稅收協議的國家的居 | | | | | 民，本公司將按10%的稅率代扣代 繳股息的個人所得稅。 | | 非個人居民 | | | | | （非中國內地登記地址） | | 20% | 如H股個人股東為與中國簽訂20% | | ...

证券代码：601607 证券简称：上海医药 编号：临2025-114 关于苹果酸司妥吉仑片（SPH3127 片）上市许可申请 获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海上药信谊药厂有限公司（以下简称"上药信谊"）收到国家药品监督管理 局（以下简称" 国家药监局"）下发的《药品注册证书》（药品批准文号：国 药准字 H20250067），由其提交的苹果酸司妥吉仑片（即 SPH3127 片，以下简称 "该药品"）的药品上市许可申请获国家药监局批准。现将相关情况公告如下： 一、药品的基本情况 药品名称：苹果酸司妥吉仑片 剂型：片剂 规格：50mg 注册分类：化学药品 1 类 申请事项：药品注册（境内生产） 上海医药集团股份有限公司 苹果酸司妥吉仑片是新一代口服非肽类小分子肾素抑制剂，通过对肾素的直 接抑制，拮抗由肾素-血管紧张素-醛固酮系统（RAAS）过度激活造成的血压上升， 适用于原发性高血压的治疗。体外和体内药效学研究均表明，苹果 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the marketing license of SPH3127 tablets, a new oral non-peptide small molecule renin inhibitor for the treatment of primary hypertension [1] Company Summary - The approved drug, SPH3127, is designed to directly inhibit renin, counteracting the blood pressure increase caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - Clinical studies have demonstrated that SPH3127 shows a clear antihypertensive effect in patients with primary hypertension, providing a new treatment option for this patient group [1] - The total research and development investment for SPH3127 has reached approximately 296 million yuan [1] Industry Summary - SPH3127 is positioned as a next-generation treatment in the hypertension market, with stronger renin activity inhibition compared to existing drugs targeting the same pathway [1] - The drug has shown efficacy in models of hypertension, chronic kidney disease, and inflammatory bowel disease, indicating its potential broader therapeutic applications [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the marketing license of SPH3127 tablets, a new oral non-peptide small molecule renin inhibitor for the treatment of primary hypertension [1] Group 1: Product Approval - The product, SPH3127 tablets (also known as Apixaban), has been granted a drug registration certificate with the approval number H20250067 [1] - The approval signifies a significant milestone for the company in expanding its product portfolio in the hypertension treatment market [1] Group 2: Product Efficacy - SPH3127 tablets directly inhibit renin, counteracting the blood pressure increase caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - Preclinical and clinical studies indicate that SPH3127 exhibits stronger renin activity inhibition compared to other drugs targeting the same pathway [1] - Clinical research has demonstrated good overall safety and clear antihypertensive efficacy in patients with primary hypertension, fulfilling a clinical need for new treatment options [1] Group 3: Research and Development Investment - The company has invested approximately 296 million yuan in the research and development of SPH3127 tablets to date [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the marketing license of its new drug, SPH3127 tablets, which is a novel oral non-peptide small molecule renin inhibitor for the treatment of primary hypertension [1] Company Summary - The drug, SPH3127 tablets, is designed to directly inhibit renin, counteracting the blood pressure increase caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - Clinical studies have demonstrated that SPH3127 tablets exhibit a clear antihypertensive effect in patients with hypertension, indicating good overall safety and efficacy [1] - The total research and development investment for SPH3127 tablets has reached approximately 296 million yuan [1] Industry Summary - SPH3127 tablets represent a new treatment option for patients with primary hypertension, addressing an unmet clinical need in this patient population [1] - The drug has shown stronger renin activity inhibition compared to other drugs targeting the same pathway, as evidenced by both in vitro and in vivo pharmacological studies [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Pharmaceuticals Xinyi, received a drug registration certificate from the National Medical Products Administration for the approval of its application for the marketing license of Apixaban Tablets, a new generation of oral non-peptide small molecule renin inhibitors [1] Group 1 - The approved drug, Apixaban Tablets, directly inhibits renin, counteracting the increase in blood pressure caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - The drug is indicated for the treatment of primary hypertension [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the marketing license of its new drug, SPH3127 tablets, which is a novel oral non-peptide small molecule renin inhibitor for the treatment of primary hypertension [1] Group 1: Drug Approval and Characteristics - The drug name is SPH3127 tablets, with the application acceptance number CXHS2400037 [1] - SPH3127 is designed to directly inhibit renin, counteracting the blood pressure increase caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - Preclinical and clinical studies indicate that SPH3127 exhibits stronger renin activity inhibition compared to other drugs targeting the same pathway, demonstrating efficacy in models of hypertension, chronic kidney disease, and inflammatory bowel disease [1] Group 2: Clinical Efficacy and Safety - Completed clinical studies show that SPH3127 has good overall safety and clear antihypertensive efficacy in patients with hypertension [1] - The drug aims to meet the clinical needs of patients with primary hypertension by providing a new treatment option [1] Group 3: Research and Development Investment - To date, approximately 296 million yuan has been invested in the research and development of SPH3127 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for its new drug, SPH3127 tablets, which are indicated for the treatment of primary hypertension [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyin Pharmaceutical Factory, has been granted a drug registration certificate for SPH3127 tablets [1] - The drug is a new generation oral non-peptide small molecule renin inhibitor [1] Group 2: Industry Context - SPH3127 tablets work by directly inhibiting renin, counteracting the blood pressure increase caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - The drug is specifically designed for the treatment of primary hypertension [1]